iSpecimen (NASDAQ:ISPC – Get Free Report) and VivoSim Labs (NASDAQ:VIVS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.
Risk and Volatility
iSpecimen has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Profitability
This table compares iSpecimen and VivoSim Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iSpecimen | -2,445.40% | -524.39% | -140.42% |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iSpecimen | $466,302.00 | 7.29 | -$10.49 million | ($56.44) | -0.02 |
| VivoSim Labs | $130,000.00 | 33.31 | -$13.84 million | ($4.47) | -0.06 |
iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
13.6% of iSpecimen shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 12.2% of iSpecimen shares are held by insiders. Comparatively, 1.0% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for iSpecimen and VivoSim Labs, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iSpecimen | 1 | 0 | 0 | 0 | 1.00 |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
Summary
iSpecimen beats VivoSim Labs on 9 of the 11 factors compared between the two stocks.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
